Pioglitazone and Losartan Modify Hemodynamic and Metabolic Parameters and Vascular Prostanoids in Fructose-overloaded Rats
Overview
Authors
Affiliations
This study analyzes the effects of losartan (AT1 blocker) and pioglitazone (insulin sensitizer), alone and in combination, in the fructose-overloaded rat, a model of metabolic syndrome. All treatments (nine weeks) reduced blood pressure and triglyceridemia and also restored the diminished release of vasodilator prostaglandins (prostacyclin in aorta and mesenteric vascular bed and prostaglandin E(2) in the latter). Pioglitazone, alone and in combination with losartan, reduced the release of the vasoconstrictor thromboxane in controls and fructose rats in both vascular preparations. In conclusion, although combination therapy and single treatments exerted similar effects, there may still be some advantage to the combined treatment.
Afzal S, Sattar M, Albokhadaim I, Attiq A, Kandeel M, Abdul Manap A PPAR Res. 2024; 2024:5868010.
PMID: 38899161 PMC: 11186691. DOI: 10.1155/2024/5868010.
Afzal S, Sattar M, Johns E, Eseyin O PLoS One. 2020; 15(11):e0229803.
PMID: 33170841 PMC: 7654782. DOI: 10.1371/journal.pone.0229803.
Green D, Sutliff R, Hart C Pulm Circ. 2011; 1(1):33-47.
PMID: 21547012 PMC: 3085428. DOI: 10.4103/2045-8932.78101.
PPARgamma as a potential therapeutic target in pulmonary hypertension.
Sutliff R, Kang B, Hart C Ther Adv Respir Dis. 2010; 4(3):143-60.
PMID: 20530063 PMC: 3978142. DOI: 10.1177/1753465809369619.
Peredo H, Mayer M, Faya I, Puyo A, Carranza A Eur J Nutr. 2008; 47(7):349-56.
PMID: 18726563 DOI: 10.1007/s00394-008-0734-7.